drugset

drugset / Trial / NCT00353756

Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease

NCT00353756 ↗

Phase 1 Unknown 52 enrolled Avidia

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether C326, a new inhibitor of IL-6, is safe in patients with Crohn's disease.

Timeline

Start: 2006-09
Primary completion: —
Completion: 2007-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	C326	Protein / enzyme biologic	—	Intravenous

Indications